It is estimated that over 6.1 million people aged 12 or older have an opioid use disorder (OUD). Medications for opioid use disorder (MOUD) are an […]

Today, FDA issued the Federal Register notice, Modifications to Labeling Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence, to encourage the submission of supplemental new […]

[12-26-2024] The Food and Drug Administration is advising consumers not to purchase or use Rhino Gummy Royal 50000, a product promoted and sold for sexual enhancement […]

[12-26-2024] The Food and Drug Administration is advising consumers not to purchase or use Rhino 11 Gummy, a product promoted and sold for sexual enhancement on […]

Summary Company Announcement Date: December 23, 2024 FDA Publish Date: December 24, 2024 Product Type: Drugs Reason for Announcement: Recall Reason Description Bottles may contain empty […]

Delivery Method: Via Email Reference #: 320-25-25 Product: Drugs Recipient: Recipient Name Mr. David Kahan Recipient Title Managing Partner Brands International Corporation 101 Chase Avenue Suite […]

Delivery Method: VIA UPS Reference #: 320-25-27 Product: Drugs Recipient: Recipient Name Mr. Alfredo Cortazar Recipient Title Owner and Chief Executive Officer (CEO) Sombra Cosmetics, Inc. […]

Delivery Method: Via Email Reference #: 320-25-28 Product: Drugs Recipient: Recipient Name Mr. Scott A. Smith Recipient Title Chief Executive Officer Viatris, Inc. 1000 Mylan Blvd.Canonsburg, […]

Delivery Method: Via Email Product: Drugs Recipient: Recipient Name Mr. RamaRao Kovoor Venkata Recipient Title General Manager – Technical/Quality Operations Akron Formulations India Private Limited 134 […]